2026-11-11. The following slide deck was published by CRISPR Therapeutics AG in conjunction with this event.
Crispr Therapeutics is rated a Buy, citing a strong balance sheet, derisked pipeline, and favorable risk/reward ratio. Discover more on CRSP in this article.
ZUG, Switzerland and BOSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior man...
Systemic sclerosis (SSc) data presented at ACR Convergence 2026 showed 83% (5/6) of patients receiving standard lymphodepletion achieved a clinical response (rCRISS-25) at Month 3, with all responders maintaining response Zugo-cel has been well tolerated in all 21 patients dosed to date, with no cytokine release syndrome (CRS) above Grade 2 and no immune effector cell-associated neurotoxicity syndrome (ICANS) or immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IE
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.
CRISPR Therapeutics (NasdaqGM:CRSP) appointed Siva Sakhamuri, Ph.D., as Chief Technical Officer, according to a recent company announcement. Dr. Sakhamuri brings experience leading technical operations and manufacturing functions at established biotechnology enterprises focused on complex biologics. His background includes work on gene editing and RNA based therapies as well as oversight of regulatory submissions and commercial launches. The appointment of Dr. Siva Sakhamuri as Chief...
CRISPR's first approved therapy is gaining traction, but the company's finances still lean on its cash reserves and an expensive pipeline.
– CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 – – CASGEVY approved in the U.K. for children 5 years of age and older with severe SCD or TDT, and in the United Arab Emirates and Bahrain for children 2 years of age and older – – FDA granted Regenerative Medicine Advanced Therapy (RMAT) designations to CTX310® for severe hypertriglyceridemia and elevated LDL-C – – Phase 1b data for CTX310 in severe hypertri
ZUG, Switzerland and BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced the appointment of Sivakesava (Siva) Sakhamuri, Ph.D., as Chief Technical Officer, effective immediately. Dr. Sakhamuri brings about 30 years of technical operations and manufacturing leadership experience across biologics, vaccines, oligonucleotides, RNA therapeutics and lipid nanoparticle (LNP) delivery. “Siva has tremendous experience advancing novel therapies across various moda
CRISPR Therapeutics (NasdaqGM:CRSP) has promoted Andrew J. Silver to Chief Financial Officer, effective October 19, 2026. Outgoing CFO Raju Prasad, Ph.D., has resigned from his role, also effective October 19, 2026. Silver steps into the finance chief role after serving within CRISPR Therapeutics, bringing internal experience to the transition. The CFO handover from Raju Prasad to Andrew J. Silver is only one piece of CRISPR Therapeutics' broader story today. Check out 2 other big wins that...
The company's gene-editing-focused platform looks promising.
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.89, moving 1.21% from the previous trading session.
Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.
ZUG, Switzerland and BOSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that its Chief Financial Offic...
The company's expertise in gene editing could lead to more breakthroughs.
This is the newest page. Registered accounts read further back.